Structure Therapeutics (NASDAQ:GPCR) Shares Gap Up - Should You Buy?

Key Points

• Shares gapped up before the open from $41.45 to $43.93 and were last trading around $42.71 on volume of 320,754 shares.
• Analysts hold a consensus of "Moderate Buy" with an average price target of $109.25, reflecting mixed coverage (3 Strong Buy, 13 Buy, 1 Hold, 2 Sell).
• The company has a $2.99B market cap and negative P/E (-53.35); it missed the most recent quarterly EPS (loss of $0.49 vs. -$0.35 expected) and institutional investors own about 91.78% of the stock.

Structure Therapeutics Inc. Sponsored ADR (NASDAQ:GPCR - Get Free Report)'s share price gapped up before the market opened on Friday . The stock had previously closed at $41.45, but opened at $43.93. Structure Therapeutics shares last traded at $42.7140, with a volume of 320,754 shares.

Analysts Set New Price Targets

A number of equities research analysts have recently issued reports on the company. Canaccord Genuity Group began coverage on Structure Therapeutics in a research report on Monday. They issued a "buy" rating and a $101.00 price target for the company. Weiss Ratings reiterated a "sell (d-)" rating on shares of Structure Therapeutics in a research report on Tuesday, April 21st. William Blair restated an "outperform" rating on shares of Structure Therapeutics in a report on Monday, March 16th. Wolfe Research initiated coverage on Structure Therapeutics in a research note on Thursday, March 26th. They issued a "peer perform" rating for the company. Finally, Citizens Jmp reduced their price target on Structure Therapeutics from $120.00 to $113.00 and set a "market outperform" rating on the stock in a report on Friday, February 27th. Three research analysts have rated the stock with a Strong Buy rating, thirteen have given a Buy rating, one has assigned a Hold rating and two have assigned a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average price target of $109.25.

Structure Therapeutics Stock Performance

The stock has a market capitalization of $2.99 billion, a price-to-earnings ratio of -53.35 and a beta of -1.17. The business has a 50-day moving average of $53.50 and a 200-day moving average of $55.50.

Structure Therapeutics (NASDAQ:GPCR - Get Free Report) last announced its earnings results on Thursday, February 26th. The company reported ($0.49) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.14). Equities analysts predict that Structure Therapeutics Inc. Sponsored ADR will post -1.36 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Structure Therapeutics

Institutional investors have recently modified their holdings of the business. Peregrine Capital Management LLC raised its holdings in Structure Therapeutics by 15.2% in the first quarter. Peregrine Capital Management LLC now owns 97,117 shares of the company's stock valued at $4,681,000 after acquiring an additional 12,793 shares in the last quarter. Janney Montgomery Scott LLC acquired a new stake in Structure Therapeutics in the first quarter valued at $329,000. Sterling Capital Management LLC acquired a new position in shares of Structure Therapeutics during the 1st quarter worth about $28,000. TrueMark Investments LLC raised its position in shares of Structure Therapeutics by 1.4% during the 1st quarter. TrueMark Investments LLC now owns 34,377 shares of the company's stock worth $1,657,000 after acquiring an additional 484 shares in the last quarter. Finally, PEAK6 LLC acquired a new position in Structure Therapeutics in the fourth quarter valued at approximately $553,000. Institutional investors and hedge funds own 91.78% of the company's stock.

Structure Therapeutics Company Profile

Structure Therapeutics NASDAQ: GPCR is a clinical‐stage biotechnology company focused on the discovery and development of oral small‐molecule therapies that target G protein‐coupled receptors (GPCRs). Leveraging advances in structural biology, computational chemistry and medicinal chemistry, the company’s scientific platform is designed to optimize binding interactions and pharmacokinetic properties, with the goal of delivering innovative treatments for metabolic and inflammatory disorders.

The company’s pipeline comprises multiple programs in various stages of preclinical and clinical development.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.